In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
Authors
Keywords
β-Lactamase inhibitor, Carbapenem-resistant, Carbapenemase, Multidrug-resistant, MK-7655, Imipenem/relebactam, Non-susceptible, Antibiotic resistance
Journal
BMC MICROBIOLOGY
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-04
DOI
10.1186/s12866-019-1522-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
- (2017) Matthew Sims et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014
- (2017) James A. Karlowsky et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia–Pacific countries: SMART 2013–2015
- (2017) James A. Karlowsky et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
- (2016) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014
- (2016) Michael D. Huband et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
- (2016) Deanna J. Buehrle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structural and Functional Aspects of Class A Carbapenemases
- (2016) Thierry Naas et al. CURRENT DRUG TARGETS
- High performance enzyme kinetics of turnover, activation and inhibition for translational drug discovery
- (2016) Rumin Zhang et al. Expert Opinion on Drug Discovery
- Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011–2014)
- (2016) Helio S. Sader et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012–2014
- (2016) Helio S. Sader et al. Surgical Infections
- Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
- (2016) Kellie Goodlet et al. Therapeutics and Clinical Risk Management
- Kibdelomycin Is a Bactericidal Broad-Spectrum Aerobic Antibacterial Agent
- (2015) Sheo B. Singh et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013
- (2015) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013
- (2015) Douglas J. Biedenbach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutant Alleles oflptDIncrease the Permeability of Pseudomonas aeruginosa and Define Determinants of Intrinsic Resistance to Antibiotics
- (2015) Carl J. Balibar et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008–2012. Results of the Study for Monitoring Antimicrobial Resistance Trends
- (2015) Krystyna M. Kazmierczak et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- The increasing threat of Pseudomonas aeruginosa high-risk clones
- (2015) Antonio Oliver et al. DRUG RESISTANCE UPDATES
- Prevalence and risk factors associated with colonization and infection of extensively drug-resistantPseudomonas aeruginosa: a systematic review
- (2015) Michael Buhl et al. Expert Review of Anti-Infective Therapy
- Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies
- (2015) Mohamed E El Zowalaty et al. Future Microbiology
- Global Assessment of Antimicrobial Susceptibility among Gram-Negative Organisms Collected from Pediatric Patients between 2004 and 2012: Results from the Tigecycline Evaluation and Surveillance Trial
- (2015) Sue C. Kehl et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-��-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea
- (2015) Hye Hyun Cho et al. JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
- Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa
- (2015) Jürg Dreier et al. Frontiers in Microbiology
- A Systematic Review and Meta-Analyses Show that Carbapenem Use and Medical Devices Are the Leading Risk Factors for Carbapenem-Resistant Pseudomonas aeruginosa
- (2014) A. F. Voor in 't holt et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®
- (2014) Timothy A. Blizzard et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- New perspectives in the management of Pseudomonas aeruginosa infections
- (2014) Dianella Savoia Future Microbiology
- Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012
- (2014) Helio S. Sader et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)
- (2014) Helio S. Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries
- (2014) M. Castanheira et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)
- (2014) Helio S. Sader et al. JOURNAL OF INFECTION
- Responses of Pseudomonas aeruginosa to antimicrobials
- (2014) Yuji Morita et al. Frontiers in Microbiology
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)
- (2013) David J. Farrell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Antibiotic Use on Carbapenem Resistance in Pseudomonas aeruginosa: Is There a Role for Antibiotic Diversity?
- (2013) C. Plüss-Suard et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011)
- (2013) Helio S. Sader et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Accumulation of carbapenem resistance mechanisms in VIM-2-producing Pseudomonas aeruginosa under selective pressure
- (2013) G. Meletis et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: Results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009
- (2013) Shio-Shin Jean et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011
- (2013) Stephen P. Hawser et al. JOURNAL OF INFECTION
- Carbapenem-resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa
- (2013) E. Fuste et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Efflux System Overexpression and Decreased OprD Contribute to the Carbapenem Resistance Among Extended-Spectrum Beta-Lactamase-Producing Pseudomonas aeruginosa Isolates from a Chinese University Hospital
- (2013) Yang Liu et al. Microbial Drug Resistance
- In VitroActivity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria
- (2012) Elizabeth B. Hirsch et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa
- (2012) Daniel J. Wolter et al. CURRENT PHARMACEUTICAL DESIGN
- Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase–producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009–2010
- (2012) Daryl J. Hoban et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010)
- (2012) Ana C. Gales et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies
- (2012) Hui Li et al. INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dendroscope 3: An Interactive Tool for Rooted Phylogenetic Trees and Networks
- (2012) Daniel H. Huson et al. SYSTEMATIC BIOLOGY
- MexXY multidrug efflux system of Pseudomonas aeruginosa
- (2012) Yuji Morita et al. Frontiers in Microbiology
- In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)
- (2011) A. Walkty et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenems: Past, Present, and Future
- (2011) Krisztina M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis
- (2011) A. R. Hauser et al. CLINICAL MICROBIOLOGY REVIEWS
- Trends in Catheter-Associated Urinary Tract Infections in Adult Intensive Care Units—United States, 1990–2007
- (2011) Deron C. Burton et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega
- (2011) F. Sievers et al. Molecular Systems Biology
- Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa
- (2009) J.-M. Rodriguez-Martinez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
- (2009) P. D. Lister et al. CLINICAL MICROBIOLOGY REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now